European Commission approves Icotyde for moderate-to-severe plaque psoriasis
The European Commission has authorised Icotyde for adults and adolescents with moderate-to-severe plaque psoriasis who are candidates for systemic therapy.
Icotyde, or icotrokinra, is an oral peptide designed to selectively target the IL-23 receptor and is approved for patients aged 12 years and older weighing at least 40kg.
The approval introduces a targeted oral systemic treatment option for plaque psoriasis and expands the range of non-injectable therapies available to eligible patients in Europe.
Field | Content |
Alert Type | Approval |
Drug Name | Icotrokinra |
Brand Name | Icotyde |
Regulatory Authority | European Commission |
Approval Type | EU marketing authorisation |
Indication | Moderate-to-severe plaque psoriasis in adults and adolescents aged 12 years and older weighing at least 40kg who are candidates for systemic therapy |
Therapy Area(s) | Dermatology; immunology |
Technology or Modality | Oral targeted peptide; IL-23 receptor antagonist |
Target | IL-23 receptor |
Geography | European Union |
What Happened | The European Commission granted marketing authorisation for Icotyde for moderate-to-severe plaque psoriasis. |
Why It Matters | Icotyde adds an oral targeted systemic therapy to a treatment landscape dominated by injectable biologics and conventional oral immunomodulators. |
Supporting Context | Icotrokinra is designed to selectively inhibit IL-23 receptor signalling, a pathway involved in the inflammatory biology of psoriasis. |
Key Takeaway | Icotyde is now authorised across the EU for eligible adults and adolescents with moderate-to-severe plaque psoriasis. |
What to Watch | European launch timing, reimbursement decisions and adoption relative to biologic and other oral systemic therapies. |
Primary Source | European Medicines Agency |
Relevant Date | 18 September 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
Kommentare